Get alerts: Tilray Brands, Canopy Growth, Aurora Cannabis, Silver Spike Investment, and Cronos Group are the five Cannabis stocks to watch today, according to MarketBeat’s stock screener tool. Cannabis stocks are shares of publicly traded companies whose primary businesses involve the cannabis industry, including cultivation, processing, distribution, retail, biotech research on cannabinoids, and ancillary products or services. For investors, these stocks typically carry higher regulatory and legal risk a ...

The Daytrip IPA series grows with Big Trip - a high-ABV brew full of flavor from the Southeast’s leading craft brand ATLANTA, Jan. 22, 2026 (GLOBE NEWSWIRE) -- SweetWater Brewing Company (“SweetWater Brewing” or “SweetWater”), the leading craft beer brand in the Southeast by Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), today announces the launch of Big Trip Double IPA, a high-ABV extension of its popular Daytrip IPA. Big Trip delivers bright citrus notes and a smooth, tropical aroma, all wrapped in a b ...

Core Viewpoint - Tilray Medical has rebranded its Italian operations to Tilray Medical Italia, reflecting its commitment to a unified medical cannabis platform in Europe and enhancing its presence in Italy's regulated medical market [1][2][4] Group 1: Strategic Update - The transition to Tilray Medical Italia signifies the company's ongoing efforts to build a scalable medical cannabis platform across Europe [2] - Tilray Medical Italia is expanding its product portfolio with medical cannabis products authorized by the Italian Ministry of Health, in partnership with Molteni Farmaceutici [3][5] Group 2: Market Positioning - Italy is identified as a strategically important market for Tilray Medical, with the rebranding aimed at strengthening local presence and aligning operations under a single global medical brand [4][10] - The company operates within Italy's established medical cannabis framework, supplying products through hospital and pharmacy channels in compliance with national regulations [5][7] Group 3: Product Offerings - Tilray Medical Italia's product portfolio includes various medical cannabis flowers and oils, all EU-GMP certified to meet diverse patient needs [8][9] - The offerings include specific THC and CBD ratios, catering to different therapeutic requirements [9] Group 4: Collaboration and Compliance - The partnership with Molteni Farmaceutici supports physician education, responsible prescribing, and patient access while ensuring high standards for product quality and compliance [6][7] - Tilray Medical Italia aims to responsibly support the evolving demand for medical cannabis in a regulated pharmaceutical environment [7][11]

The company's international cannabis sales soared by 36%, and it cut its losses in half.For years, Tilray Brands (TLRY 7.46%) has been an incredibly risky investment to hang on to, generating brutal returns. During the past five years, it has lost 95% of its value. Between its lackluster prospects and poor financial results, the business has simply not given investors much of a reason to be bullish about its future.Earlier this month, however, the company posted some encouraging results. Its top line hit a ...

Key Takeaways TLRY posted one of its strongest international quarters as cannabis revenues rose 36% year over year.Tilray Brands scaled back Canadian supply and redeployed production to international markets globally.TLRY is expanding internationally via European cannabis scale and new beverage launches in the U.K.Tilray Brands (TLRY) delivered one of its strongest international quarterly performances in the second quarter of fiscal 2026. Revenues from the company’s high-margin international cannabis busine ...

Key Points Tilray's latest financial results were fairly strong. The company could have a large market opportunity in the U.S. However, Tilray still faces significant challenges. 10 stocks we like better than Tilray Brands › Is Tilray Brands (NASDAQ: TLRY) finally turning things around? After terrible performances during the past five years -- when the business lost more than 90% of its market value -- the company has had strong momentum in the past six months. Much of that was due to positive r ...

President Donald Trump's recent executive order urging the Department of Justice to reschedule cannabis to Schedule 3 is being hailed as the "most consequential federal cannabis policy shift" in over 50 years.Dan Ahrens, portfolio manager of the AdvisorShares Pure US Cannabis ETF (NYSE:MSOS) , says the move could finally dismantle the crippling tax regime that has stifled American cannabis operators for decades.The End Of ‘Narcotics Trafficker’ StatusAhrens told Yahoo Finance that the immediate financial ca ...

Industry Overview - The cannabis industry is projected to reach new heights by 2026, driven by increased partnerships and consumer demand, alongside a favorable political climate in the US [1][3] - Positive speculation surrounds the cannabis sector for 2026, suggesting potential growth in marijuana stocks [1] Company Performance - Tilray Brands, Inc. reported a record Q2 fiscal 2026 net revenue of $218 million, indicating a strong financial position and reaffirming full-year adjusted EBITDA guidance [6][7] - Canopy Growth Corporation has taken steps to recapitalize its balance sheet, extending the maturity dates of all outstanding debts to January 2031, which positions the company for future growth [11][12] - Village Farms International, Inc. has entered the Dutch cannabis market by launching 10 new product offerings through its subsidiary Leli Holland [14] Investment Opportunities - Key marijuana stocks to watch for potential investment returns include Tilray Brands, Inc. (NASDAQ: TLRY), Canopy Growth Corporation (NASDAQ: CGC), and Village Farms International, Inc. (NASDAQ: VFF) [8]

Key Takeaways TLRY delivered record Q2 net revenues of $217.5M, up 3% year over year, led by international operations.TLRY's distribution revenues rose 26% to $85.3M, while international cannabis sales jumped 36% in Q2.TLRY scaled back Canadian wholesale shipments to focus on higher-margin international cannabis markets.Tilray Brands (TLRY) delivered net revenues of $217.5 million in the second quarter of fiscal 2026, a quarterly record driven by strong results in the company’s international operations. On ...

Key Takeaways TLRY delivered record Q2 net revenues of $217.5M, up 3% year over year, with narrower losses.TLRY saw global cannabis jump 36% and distribution rise 26%, offsetting a 21% decline in beverage revenues.TLRY reaffirmed full-year adjusted EBITDA guidance and ended Q2 with improved net cash and strong liquidity.Tilray Brands (TLRY) posted its second-quarter fiscal 2026 results last Thursday after the closing bell. The company’s net revenues reached a record $217.5 million, up 3% on a year-over-year ...